TerminatedPhase 4

Tranexamic Acid in Radical Resection and Endoprosthetic Reconstruction

Stopped: recruitment stalled

United States12 participantsStarted 2020-01-28

Plain-language summary

This study intends to determine if any correlation exists between administration of TXA or not to musculoskeletal oncology patients undergoing endoprosthetic reconstruction and blood loss and blood transfusion rates.

Who can participate

Age range18 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients undergoing wide resection of a malignant bony tumor of the lower extremity with endoprosthetic reconstruction. * Patients undergoing a resection of soft tissue sarcoma measuring \> 5cm. Exclusion Criteria: * Patients undergoing revision endoprosthetic reconstruction * Patients with known coagulopathy * Known history of DVT or embolic disease * Benign tumors * Patients with allergy to TXA * Those refusing blood products * Those concurrently on anti-coagulant therapy * Pregnant and/or nursing women * Vulnerable populations as defined by the KUMC IRB

What they're measuring

Perioperative Blood Loss

Timeframe: During surgical procedure, 4 to 6 hours

Trial details

NCT IDNCT04347122

SponsorUniversity of Kansas Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-08-18

Results submitted2024-11-03

View on ClinicalTrials.gov More Musculoskeletal Cancer trials